Leerink on Medline Inc (MDLN): 'view the recent stock weakness as primarily timing-related rather than indicative of any structural business deterioration'

June 10, 2026 6:22 AM

Leerink analyst Michael Cherny reiterated an Outperform rating and $52.00 price target on Medline Inc (NASDAQ: MDLN).The analyst comments "We ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found